Medicare to Cover GLP-1 Weight-Loss Drugs Starting July 1
Eligible Medicare beneficiaries will gain access to GLP-1 weight-loss medications for $50/month, a historic first for the program.
For the first time in its history, Medicare will cover GLP-1 medications prescribed specifically for weight loss, a significant policy shift that takes effect July 1. Older Americans who meet eligibility requirements will be able to access these drugs — the same class that includes widely discussed brand names — at a capped cost of $50 per month, a price point that reflects both the program's negotiating structure and the broader push to make obesity treatment more accessible to seniors.
The change matters because GLP-1 drugs have historically been available under Medicare only when prescribed for type 2 diabetes or cardiovascular risk reduction, leaving millions of obese but otherwise metabolically stable beneficiaries without coverage. Expanding that access represents a meaningful acknowledgment that obesity itself is a treatable chronic condition rather than a lifestyle choice, a framing that advocates have pushed for years.
Read more New Bill Would Cap Medicare Out-of-Pocket Costs at $5,000 Annually →
Yet the opportunity comes with trade-offs that prospective users should weigh carefully. GLP-1 medications are associated with side effects including nausea, gastrointestinal distress, and, importantly, muscle loss — a concern that carries heightened stakes for older adults, whose baseline muscle mass already tends to decline with age. Clinicians generally recommend that patients on these drugs engage in resistance exercise and monitor protein intake to offset lean-tissue depletion, though adherence to those protocols varies widely in practice.
The $50 monthly cost figure is notable in context: brand-name GLP-1 drugs can list for well over $1,000 per month without coverage, meaning the Medicare benefit represents a dramatic reduction in out-of-pocket exposure for eligible seniors. Still, beneficiaries should confirm their specific plan's formulary and any prior-authorization requirements before July 1, since implementation details can vary across Medicare Advantage and Part D plans.
Continue reading at MarketWatch.com
